Small-cell lung cancer (SCLC) represents about 15% of all lung cancers and is marked by
an exceptionally high proliferative rate, strong predilection for early metastasis and poor …

Small cell lung cancer (SCLC) is an exceptionally lethal malignancy for which more effective
therapies are urgently needed. Several lines of evidence, from SCLC primary human …

Introduction Recent studies have identified subtypes of small cell lung carcinoma (SCLC)
defined by the RNA expression of ASCL1, NEUROD1, POU2F3, and YAP1 transcriptional …

Single-cell RNA sequencing (scRNA-seq), a technology that analyzes transcriptomes of
complex tissues at single-cell levels, can identify differential gene expression and epigenetic …

Single-cell sequencing-based methods for profiling gene transcript levels have revealed
substantial heterogeneity in expression levels among morphologically indistinguishable …

Lineage plasticity, the ability of cells to transition from one committed developmental
pathway to another, has been proposed as a source of intratumoural heterogeneity and of …

Intratumor heterogeneity, which fosters tumor evolution, is a key challenge in cancer
medicine. Here, we review data and technologies that have revealed intra-tumor …

Small-cell lung cancer (SCLC) is a deadly tumour accounting for approximately 15% of lung
cancers and is pathologically, molecularly, biologically and clinically very different from other …

Metastasis is the main cause of death in people with cancer. To colonize distant organs,
circulating tumour cells must overcome many obstacles through mechanisms that we are …

Immunotherapy has revolutionized cancer therapy, largely attributed to the success of
immune-checkpoint blockade. However, there are subsets of patients across multiple …